BioArctic AB, a Swedish biopharma company, has partnered with Novartis Pharma AG to develop a potential treatment using BioArctic’s BrainTransporter technology alongside an undisclosed target in neurodegeneration. The agreement includes an initial research collaboration with a $30 million upfront payment to BioArctic. Novartis has the option to license any drug candidate resulting from the collaboration, with additional payments of up to $772 million possible if they exercise this option. BioArctic would also receive royalties on future global product sales if the treatment reaches the market.
The collaboration will focus on creating a new drug candidate by combining BioArctic’s BrainTransporter technology with a Novartis proprietary antibody. Should Novartis choose to license the drug candidate, they would take over responsibility for its global development and commercialization. This marks BioArctic’s third partnership utilizing the BrainTransporter technology. The platform, which facilitates the passage of biological drugs into the brain, has shown promise in improving drug efficacy, safety, and dosing convenience by enabling active transport across the blood-brain barrier.
The CEO of BioArctic, Gunilla Osswald, expressed excitement about the partnership with Novartis, highlighting the potential of the BrainTransporter platform to enhance treatments for neurological disorders. Novartis aims to leverage this technology to optimize the delivery of therapeutic agents and improve outcomes for patients with severe neurological conditions. The collaboration underscores Novartis’ commitment to advancing science and discovering treatments for nervous system disorders, as emphasized by Sophie Parmentier Batteur, head of neurodegeneration research at Novartis.
BioArctic’s BrainTransporter technology has broad applications beyond this collaboration, offering potential partnering opportunities in various therapy areas for delivering biologics and other modalities. The platform’s ability to enhance brain distribution of drugs could benefit multiple in-house projects and future partnerships with pharmaceutical companies. As a research-focused biopharma company, BioArctic is dedicated to developing innovative treatments that target neurodegenerative diseases, building on its success with Leqembi (lecanemab), the first drug proven to slow disease progression and reduce cognitive impairment in early Alzheimer’s disease.
Key Takeaways:
– BioArctic’s collaboration with Novartis aims to develop a new treatment for neurodegenerative diseases using the BrainTransporter technology.
– Novartis has the option to license any resulting drug candidate, with potential payments totaling up to $772 million for BioArctic.
– The BrainTransporter platform offers a versatile approach to enhancing drug delivery into the brain, with applications across various therapy areas.
– This partnership underscores BioArctic’s commitment to advancing treatments for neurological disorders and leveraging innovative technologies for improved patient outcomes.
Tags: biopharma
Read more on pharmabiz.com